VOYA Investment Management
VTGN icon

VOYA Investment Management’s VistaGen Therapeutics VTGN Stock Holding History

VOYA Investment Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,504
Closed -$66K – 2979
2022
Q2 		$66K Hold
2,504
– – ﹤0.01% 2704
2022
Q1 		$93K Hold
2,504
– – ﹤0.01% 2520
2021
Q4 		$146K Sell
2,504
-39
-2% -$2.54K ﹤0.01% 2597
2021
Q3 		$209K Hold
2,543
– – ﹤0.01% 2553
2021
Q2 		$240K Buy
+2,543
New +$188K ﹤0.01% 2497

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VOYA Investment Management's VTGN Position: Q3 2022 in Review

VOYA Investment Management sold out of VistaGen Therapeutics (VTGN) in Q3 2022, closing a stake of 2,504 shares — an estimated $66K sold.

VOYA Investment Management first reported a position in VTGN in Q2 2021 and held it in 5 quarters. The position peaked at $240K in Q2 2021. 92 funds tracked by Wall St. Rank hold VTGN as of Q3 2022.

  • VOYA Investment Management reported no remaining VistaGen Therapeutics position as of Q3 2022 after selling out during the quarter.
  • VOYA Investment Management sold 2,504 VistaGen Therapeutics shares in Q3 2022, an estimated $66K.
  • VOYA Investment Management first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 5 quarters.
  • VOYA Investment Management's VistaGen Therapeutics position peaked at $240K in Q2 2021.
  • 92 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2022.

Based on VOYA Investment Management's 13F filing for Q3 2022, filed 14 Nov 2022.